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ScienceDirectThe deployment of effective veterinary vaccines has had a
major impact on improving food security and consequently
human health. Effective vaccines were essential for the global
eradication of Rinderpest and the control and eradication of
foot-and-mouth disease in some regions of the world. Effective
vaccines also underpin the development of modern intensive
food production systems such as poultry and aquaculture.
However, for some high consequence diseases there are still
significant challenges to develop effective vaccines. There is a
strong track record in veterinary medicine of early adoption of
new technologies to produce vaccines. Here we provide
examples of new technologies to interrogate B cell responses
and using structural biology to improve antigens.
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Protective antibody responses are an essential component
of the responses induced by effective vaccines for a
number of pathogens. Antibodies can recognise short
peptides that contain key residues that form the epitope,
but these peptides might lack additional residues that are
outside of the linear epitope, so they do not represent the
structures recognised by antibodies in immunised or
infected animals. Currently, quantitative rules linking
sequence, structure, immunogenicity, and protection
are still lacking. The induction of robust protective
immune responses in livestock species still relies on
the presentation of antibody epitopes in the context of
the whole pathogen or individual proteins. Therefore, the
immediate application of structural vaccinology to
enhance protective antibody responses will be the engi-
neering of proteins to maintain epitopes rather than thewww.sciencedirect.com use of isolated epitopes [1]. The use of structural infor-
mation in vaccine design will allow proteins to be modi-
fied to produce more stable vaccine antigens to ensure the
structure of key epitopes are maintained during vaccine
production, distribution and application. There are two
examples of the application of structural vaccinology for
vaccine design that have been validated by in vivo proof of
concept studies in the livestock target species, these are
FMD virus like particle (VLP) vaccines and bovine RSV
(bRSV) fusion (F) protein.
Structure-based vaccine design as a route to
broadly protective PRRS vaccines
PRRS continues to be the key economically important
pig disease worldwide. The causative PRRS viruses
(PRRSV) are rapidly evolving, as most dramatically illus-
trated by the emergence of highly pathogenic variants in
Southeast Asia and Eastern Europe [2–4]. Thus, more
efficacious control strategies are urgently sought. Current
vaccines can confer protection from disease but show
variable efficacy against challenge with heterologous
strains [5–12]. A variety of experimental subunit
approaches have been evaluated as potential next-gener-
ation vaccines but have at best conferred only limited
protection [13–18]. The limitations of both existing and
experimental vaccines support the proposition that a new
approach is required to design immunogens capable of
providing broad protection against this hypervariable
pathogen. Neutralising antibodies (nAbs) can provide
immunity against PRRSV as demonstrated by a dose-
dependent protective effect conferred by passive transfer
of homologous PRRSV-neutralising sera [19]. However,
the PRRSV-specific Ab responses measurable from 7 days
post-infection is non-neutralising, and nAb responses are
often not observed until at least four weeks post-infection
and titres, when measurable, are often lower than those
elicited by other viral infections [20,21]. Collectively,
these observations suggest that PRRSV has evolved strat-
egies to modulate the B cell response to evade the
induction of protective nAbs via the glycan shielding of
neutralising epitopes and/or the promotion of responses
against non-neutralising decoy epitopes [22]. These data
also suggest that vaccination strategies that induce high-
titre nAbs would be efficacious. The development of such
a strategy would benefit from an improved understanding
of the neutralising epitopes on PRRSV that confer pro-
tection. Since a lack of cross-protection is a major con-
straint in the development of PRRSV vaccines, the iden-
tification of conserved epitopes is of paramount
importance.Current Opinion in Virology 2018, 29:33–38
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and GP4 [23,24] of PRRSV-1 and GP5 of both PRRSV-1
and PRRSV-2 [25–27]. The complexity of the nAb
response to PRRSV and the limitation of current under-
standing was illustrated by recent studies investigating
the cross-neutralisation of field strains [28,29]. Evaluation
of the neutralisation of PRRSV-1 isolates by a panel of
hyperimmune sera revealed significant differences in the
sensitivity of PRRSV strains to neutralisation; however,
no correlation was observed with known linear nAb
epitopes or N-linked glycosylation sites [29]. Interest-
ingly, 10% of sera exhibited significant neutralising activ-
ity against all isolates, suggesting that these sera contain
nAb specific for conserved epitopes that may be poorly
exposed and consequently weakly immunogenic in most
strains. Whilst it may be suggested that differences in
residues outside the described linear epitopes altered
accessibility, an alternative explanation is the presence
of as-yet-unidentified conformational nAb epitopes. In
support of this, a study of PRRSV-2 infected pigs identi-
fied a single animal with a broadly nAb response that even
neutralised PRRSV-1 [30]. The deletion of a single non-
conserved amino acid in the M protein conferred resis-
tance to this response, although it remains to be deter-
mined whether this mutation is altering a conformational
epitope or blocking access to a linear epitope. Evidence
for the natural occurrence of broadly nAbs was presented
in a recent study of two US sow herds with multiple
exposures to PRRSV that revealed sera capable of neu-
tralisation of strains spanning both PRRSV species [31].
The identification of nAb epitopes and particularly the
conserved viral structures recognised by these broadly
nAbs would lay the solid basis on which to rationally
develop a much-needed second generation vaccine to
prevent and control PRRS.
Identification of the epitopes recognised by broadly nAbs
is an area of intense recent research in the context of a
number of highly variable human viruses [32–35]. Central
to this effort are methods to generate and analyse the
specificity of naturally occurring monoclonal antibodies
(mAbs). Recent advances in methodologies to analyse
antigen-specific B cells and their immunoglobulin genes
are now providing large numbers of human mAbs for
application both as therapeutics and in the design of novel
immunogens [36]. We are pursuing two complementary
approaches to isolate broadly neutralising mAbs from a
cohort of pigs hyper-immunised by sequential challenge
infections with heterologous PRRSV strains. The first
approach involves the use of a retroviral vector to consti-
tutively express the B cell lymphoma-6 (Bcl-6) transcrip-
tion factor and the anti-apoptotic Bcl-2-like protein 1
(Bcl-xL) in memory B cells [37]. With co-stimulation,
transduced cells proliferate, secrete their Abs and retain
surface immunoglobulin expression. These cells are
therefore amenable to both enrichment/cloning by anti-
gen-baiting and direct analysis of Ab specificity in cellCurrent Opinion in Virology 2018, 29:33–38 culture supernatants. This approach has been success-
fully deployed to isolate human mAbs capable of broadly
neutralising human parechovirus [38], RSV [37] and
influenza A virus [39], to eventually identify epitopes
as vaccine targets. Significantly, this approach has been
used to successfully immortalise B cells from rabbits,
mice, llamas and non-human primates [37,40]. The
second approach, which builds on our experiences in
isolating FMDV-neutralising bovine mAbs, is using
high-throughput sequencing of immunoglobulin genes
from plasma B cells. Bioinformatic analysis will identify
over-represented clonal families that will be expressed as
recombinant mAbs using an established high-throughput
protein expression pipeline. Cross-neutralising mAbs will
be identified by in vitro screening epitopes elucidated by
cryo-EM structural analysis of mAb complexed to purified
PRRSV virions. We hope that the isolation of these mAbs
will contribute to both our understanding of the nAb
response to PRRSV and allow epitopes to be resolved
that may be engineered as immunogens to induce cross-
protective immunity.
Structural vaccinology approaches to induce
enhanced immune responses against FMDV
and RSV in cattle
FMD is endemic in large parts of South America, Africa,
The Middle East and Asia and is, globally, the most
economically important infectious disease of livestock,
affecting cattle, pigs, sheep, goats and other artiodactyl
species (Figure 1). In endemic countries, FMD not only
affects national and international trade, but also impacts
on the whole livestock industry with damaging conse-
quences for local farmers and, invariably, loss of income.
Livestock health is clearly linked to human health and
prosperity, hunger, malnutrition, and poor health are
widespread and stubborn development challenges. Rou-
tine vaccination programmes are employed in the
endemic regions of the world but regular immunisation
is required. Improved vaccines, in terms of stability and
protection against emerging FMDV, are essential for
disease control and to establish and maintain FMD-free
status in many regions of the world. The current FMD
vaccines are inactivated whole virus preparations which
contain an adjuvant to enhance the immune response.
There are 7 FMDV serotypes: O, A, Asia1, C and three
strains circulating predominately in sub-Saharan Africa,
SAT (South Africa Territories) 1, 2 and 3.
There is currently a massive shortfall in the availability of
vaccines, most strikingly in Africa. There is a significant
impediment to building new high disease containment
facilities to increase the production of conventional killed
virus vaccines because of the high initial and on-going
costs. A particular difficulty for FMDV is that effective
vaccination requires the presence of intact inactivated
virus or VLPs. Individual proteins or peptides havewww.sciencedirect.com
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Precise changes to the structure of viral proteins can significantly enhance their antigenic properties. The example shown on the left is a foot-and-
mouth disease virus capsid that readily dissociates into pentamers that will not induce protective immune responses. However, if point mutation is
introduced at the boundary of the pentamers to form a new covalent bond, compare left and right lower structures, the intact capsids are
stabilised and can survive heat or acid treatment and induce protective responses.proven to be insufficiently immunogenic for use as vac-
cine antigen.
We are aiming to address these challenges. Detailed
knowledge of the atomic structure of the different ser-
otypes and strains of the virus has resulted in significant
advances to produce recombinant FMD VLPs as effec-
tive vaccines that can be manufactured in conventional
low containment facilities. Novel methods have been
developed to design specific changes in the VLP to allow
them to remain intact during production, formulation,
storage and transport and so remain immunogenic.
Initial studies have reported a stable disulphide bond at
the icosahedral two-fold axis between adjacent pentamers
in the A22 virus, thus allowing the production ofwww.sciencedirect.com thermostable and pH-stable recombinant empty particles
[41]. However, there is not one simple solution to
stabilise all serotypes and strains of FMDV. Conse-
quently, a highly restrained atomistic molecular dynamics
simulation in silico method has been developed to focus
on the appropriate part of the complete virion to effi-
ciently and reliably calculate the changes in binding free
energy for interactions between adjacent pentamers
within the FMDV capsid. Single-residue mutations were
identified that resulted in enhanced stability by hydro-
phobic stacking of aromatic side chains of residues intro-
duced at position 93 of the FMDV capsid protein VP2 at
the two-fold axis between adjacent pentamers.
In vitro assays were used to determine that the noncova-
lent stabilisation particles, using hydrophobic stacking,Current Opinion in Virology 2018, 29:33–38
36 Preventive and therapeutic vaccinesproduced similar stability to covalently cross-linked A22
particles. The potential value of this increased stabilisa-
tion was demonstrated in vivo. After storage for 1 or
6 months at 4 C, stabilised particles formulated in oil
adjuvant produced substantially higher virus neutralising
antibody titres in guinea pigs than did wild-type particles
[42,43].
Bovine respiratory syncytial virus (bRSV) is responsible
for the majority of respiratory disease in cattle annually
resulting in considerable morbidity and losses [44].
Human RSV (hRSV) is responsible for over 3 million
hospitalisations for severe respiratory illness in young
children and the elderly each year and for which no
licensed vaccine is available [45]. Although several
licensed vaccines are available for bRSV, none are fully
effective, inactivated bRSV vaccines may enhance dis-
ease and have reduced efficacy in the presence of mater-
nal antibodies [46,47] and live vaccines can exacerbate
bRSV disease [48]. Recombinant subunit-based vaccines
have the potential to induce protective antibody
responses with the benefits of ease of manufacture and
long-term stability.
The most potently neutralising RSV antibodies identified
thus far target the pre-fusion (pre-F) form of the RSV F
glycoprotein [49,50]. The pre-F form of RSV F is meta-
stable and spontaneously undergoes structural rearrange-
ments to the post-fusion (post-F) form, which no longer
presents epitopes for many potently neutralising antibo-
dies. Structure-based design has been applied to engineer
thermostable versions of the pre-F hRSV F glycoprotein
by the addition of new disulphide covalent bonds and by
cavity filling through the introduction of residues with
hydrophobic side chains. These mutations stabilised the
pre-F conformation and retained the epitopes to induce
highly potent neutralising antibodies [51,52]. The F
glycoprotein of bRSV has greater than 80% sequence
identity with that of hRSV2 so similar mutations were
transferred to bRSV to create bRSV F trimer immunogens
stabilised in the pre-F state. Inoculation of calves with the
stabilised pre-F bRSV trimers resulted in complete
microbiological and clinical protection to heterologous
bRSV challenge. The high titre protective response eli-
cited by the prefusion-stabilised F in calves suggests
similar highly protective immune responses can be gen-
erated in humans immunised with similarly stabilised
pre-F proteins [53].
Conclusions
Recent developments in veterinary vaccinology have
paralleled the scientific advances and understanding in
areas of immunology, molecular and structural biology of
viruses, virus–host interactions and molecular pathogen-
esis of important infectious viral diseases of different
livestock species. We draw attention to the value of
applying structure-based vaccine designs to induceCurrent Opinion in Virology 2018, 29:33–38 broadly-protective immune responses in the fight against
viral infections such as PRRS. The significance of taking
advantage of structural insights to develop stable protec-
tive antigens to induce enhanced immune responses
against diseases such as FMD and RSV, will also be
valuable as a ‘one health’ concept in protecting animals
and humans through innovative vaccines.
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